Organisation mondiale de la santé (OMS) · Technical Documents

Polio Bulletin - 2014, Issue no. 15 (Week 29)

21 juillet 2014 Organisation mondiale de la santé

Le texte intégral est hébergé par l’organisation qui le publie. lawenc.com indexe les métadonnées et renvoie vers la source officielle.

Texte intégral

2014 Issue No. 15 - Week 29 (as of 21 July 2014) HIGHLIGHTS An important opportunity amid a crisis Vaccinating those displaced from North Waziristan The displacement of more than 900,000 people from North Waziristan in Pakistan’s Federally Administered Tribal Areas (FATA) increases the risk that polio will spread, as the virus travels with people UNICEF/Mian Khursheed as they move out to other parts of the country. Due to a ban on polio vaccination since June 2012, the area has suffered 55 of the country’s 94 cases in 2014. However, this displacement also creates an important opportunity. For the first time in more than two years, vaccinators can reach large numbers of children who could not previously get vaccine. Between 21 May and 15 July, 406,051 doses of oral polio vaccine were administered at vaccination points set up along major transit routes on the way out of North Waziristan. Emergency vaccination campaigns have also been held in surrounding areas, including weekly activities in parts of Khyber Pakhtunkhwa and FATA. This week’s campaign was reported to have reached almost 550,000 children. Afghanistan is also doing its part to protect both the displaced and host communities against polio. More than 35,000 displaced children under the age of 10 are reported to have received a dose of oral polio vaccine as they entered the Afghan provinces of Paktyka and Khost. For more, please see the article “Reaching the unreached with polio drops in North Waziristan”, on the End Polio Pakistan website. Source: www.polioeradication.org

Polio Bulletin 90% 80% 70% 60%

Chart 1. Non-polio AFP rate and adequate specimen collection rate, 2012–2014* 3.0 2.5 100%

Chart 2. Percent cases with pending classification > 90 days after onset, 2014 CHN Cases with adequate specimens (%)

18.4% 25.0% 0.0% 10.5% 18.8% 85.7% 14.3% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90%

KHM LAO MYS PHL PNG VNM

Non-polio AFP rate

2.0 1.5 1.0 0.5 0.0 12 13 14 CHN 12 13 14 KHM 12 13 14 LAO 12 13 14 MYS 12 13 14 PHL 12 13 14 PNG 12 13 14 VNM

50% 40% 30% 20% 10% 0%

* AFP rate annualized as of week 29

Chart 3. Polio immunization status of reported AFP cases, 2014 100% 100%

Chart 4. Percentage of samples received at the lab ≤ 3 days of collection, 2014

80%

80% 59% 52%

60%

40%

40% 29%

35%

20% 20%

0% CHN KHM LAO MYS 1-2 doses

PHL 0 doses

PNG Unknown

VNM

0% CHN

0% KHM

0% LAO MYS PHL

0% PNG VNM

≥ 3 doses

CONTACT US Expanded Programme on Immunization Regional Office for the Western Pacific World Health Organization P.O. Box 2932, 1000 Manila, Philippines Phone: +63 2 5288001 Fax: +63 2 5211036, 5260279 Email: WPR_EPIdata@wpro.who.int Web: www.wpro.who.int/immunization

Note: Priority countries were selected for the charts. Official WHO acronyms have been used for abbreviation: CHN (China), KHM (Cambodia), LAO (Lao People’s Democratic Republic), MYS (Malaysia), PHL (Philippines), PNG (Papua New Guinea), and VNM (Viet Nam).

Table 1A. Classification of AFP cases with onset in 2013 and key surveillance indicators 2012 Classification Total reported cases Annual expected cases <15 years of age Pending Total reported cases Confirmed wild poliovirus Vaccinederived poliovirus (VDPV) Non-polio AFP rate % % with % with % with any investigated 60-day adequate 3 2 days of ≤ specimen 5 specimens 2 4 follow-up notification ≥ 80% ≥ 80% ≥ 80% Latest report date 6 Days since last report 7

2013 Indicators

Poliocompatible

Discarded (Non-polio)

Total

> 90 days 1 # (%)

≥1

Australia Brunei Darussalam Cambodia China Hong Kong (China) Japan Lao People's Democratic Republic Macao (China) Malaysia Mongolia New Zealand Papua New Guinea Philippines Republic of Korea Singapore Viet Nam Pacific island countries Total 1. 2. 3. 4. 5. 6. 7.

56 1 107 6173 14 0 55 0 141 9 8 10 403 95 10 514 4 7600

43 1 45 2225 8 167 25 1 77 7 9 30 378 76 6 241 10 3349

62 1 73 5623 12 0 48 1 155 7 12 18 277 84 7 459 8 6847

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

1 0 0 1 0 0 0 0 0 0 0 2 0 0 0 0 4

61 1 73 5622 12 48 1 155 7 12 18 275 84 7 459 7 6842

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1

0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (12.5%) 1 (0.0%) Green Yellow Red

1.44 1.00 1.62 2.53 1.50 1.92 1.00 2.01 1.00 1.33 0.60 0.73 1.11 1.17 1.90 0.80 2.04

39% 100% 81% 93% 100% 58% 100% 83% 86% 50% 28% 68% 93% 71% 97% 63% 91%

71% 100% 96% 99% 100% 90% 100% 100% 100% 83% 83% 96% 100% 100% 99% 100% 99%

100% 100% 78% 100% 100% 98% 100% 85% 100% 83% 83% 98% 94% 86% 92% 100% 98%

0% 100% 98% 100% 100% 100% 100% 100% 50% 100% 100% 100% 67% 86%

18-Jul-14 06-Feb-14 13-Mar-14 28-May-14 06-Feb-14 26-May-14 14-Jan-14 31-Mar-14 07-Mar-14 27-Feb-14 26-Feb-14 08-Apr-14 20-Mar-14 08-Jan-14 17-Apr-14 14-Jul-14

Number (%) of reported cases pending classification more than 90 days from date of onset of paralysis to date of last report Percentage of reported cases with two stool specimens collected 24 hours apart and within 14 days of onset of paralysis Percentage of reported cases with at least one specimen Percentage of reported cases investigated within two days of notification Percentage of reported cases with inadequate specimens followed-up within 60 days of onset of paralysis Report date is fixed as soon as all cases for the year have been classified Countries are expected to submit data at least once per month to WPRO

Reached or surpassed target Nearly reached target: 0.5–0.99 for non-polio AFP rate; 60–79% for other indicators Substantially below target

Polio Bulletin

Table 1B. Classification of AFP cases with onset in 2014 and key surveillance indicators 2013 Classification Total reported cases Annual expected cases <15 years of age Pending Total reported cases Confirmed wild poliovirus Vaccinederived poliovirus (VDPV) Non-polio AFP rate 2 % % with % with % with any investigated adequate 60-day 4 2 days of ≤ specimen 6 specimens 3 5 follow-up notification ≥ 80% ≥ 80% ≥ 80% Latest report date Days since last report 7

2014 Indicators

Poliocompatible

Discarded (Non-polio)

Total

> 90 days 1 # (%)

≥1

62 1 73 5623 12 0 48 1 155 7 12 18 277 84 7 459 8 6847

44 1 45 2225 8 167 25 1 77 8 9 30 378 76 6 241 10 3351

18 0 8 2392 9 0 11 1 76 3 2 7 144 53 4 77 6 2811

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

15 0 1110 7 5 1 58 1 0 0 64 43 4 13 0 1321

3 8 1282 2 6 0 18 2 2 7 80 10 0 64 6 1490

2 (11.1%) 2 (25.0%) 440 (18.4%) 1 (11.1%) 0 (0.0%) 0 (0.0%) 8 (10.5%) 0 (0.0%) 1 (50.0%) 6 (85.7%) 27 (18.8%) 0 (0.0%) 0 (0.0%) 11 (14.3%) 3 (50.0%) 501 (17.8%) Green Yellow Red

0.73 0.32 1.93 2.02 0.79 1.79 1.77 0.67 0.40 0.42 0.68 1.25 1.20 0.57 1.08 1.50

39% 88% 92% 89% 55% 0% 75% 100% 50% 0% 60% 81% 75% 97% 83% 89%

72% 100% 99% 100% 100% 100% 100% 100% 100% 100% 88% 100% 100% 100% 100% 98%

83% 100% 100% 100% 91% 100% 55% 100% 100% 57% 97% 96% 100% 88% 100% 98%

0% 0% 77% 100% 0% 100% 32% 0% 0% 7% 80% 100% 0% 0% 54%

25-Jun-14 06-Feb-14 02-May-14 09-Jul-14 02-Jul-14 06-May-14 21-Jul-14 20-Jun-14 07-Jul-14 16-May-14 17-Jul-14 08-Jul-14 18-Jul-14 09-Jul-14 26-May-14 14-Jul-14

26 165 80 12 19 76 0 31 14 66 4 13 3 12 56 7

Number (%) of reported cases pending classification more than 90 days from date of onset of paralysis to date of last report Annualized non-polio AFP rate per 100 000 population under 15 years of age Percentage of reported cases with two stool specimens collected 24 hours apart and within 14 days of onset of paralysis Percentage of reported cases with at least one specimen Percentage of reported cases investigated within two days of notification Percentage of reported cases with inadequate specimens followed-up within 60 days of onset of paralysis Countries are expected to submit data at least once per month to WPRO

Reached or surpassed target Nearly reached target: 0.5–0.99 for non-polio AFP rate; 60–79% for other indicators Substantially below target

Polio Bulletin

Table 2A. Laboratory investigation of AFP cases with onset in 2013 and key laboratory indicators Virus isolation results Country National polio laboratory Total no. of AFP L20B cases with specimens positive L20B positive + NPEV NPEV only Pending ≤ 14 Negative days Intratypic % % results differentiation Latest Pending reported specimens / Sequencing positive report date > 14 2 ≤ 14 days for NPEV lab 1 days ≥ 80% No. of isolates referred Type 1 W ild Sabin VDPV Wild Type 2 Sabin Intratypic differentiation (ITD) results Type 3 VDPV Wild Sabin VDPV NPEV 3

Pending ITD

% ITD results Discordant reported ≤ 7 days of pending receipt sequencing ≥ 80%

Australia Brunei Darussalam Papua New Guinea Pacific island countries Japan Cambodia Lao People's Democratic Republic Malaysia Mongolia New Zealand Philippines Republic of Korea Singapore Viet Nam, North Viet Nam, South China China, Anhui China, Beijing China, Fujian China, Gansu China, Guangdong China, Guangxi China, Hebei China, Heilongjiang China, Henan China, Hunan China, Jiangsu China, Jiangxi China, Jilin China, Shaanxi China, Shandong China, Shanghai China, Shanxi China, Sichuan China, Tianjin China, Xinjiang China, Yunnan China, Zhejiang China, Chongqing China, Guizhou China, Hainan China, Hubei China, Liaoning China, Neimongol China, Ningxia China, Qinghai China, Tibet Hong Kong (China) Macao (China) Total

VIDRL VIDRL VIDRL VIDRL NIID NIID NIID IMR PHI IESR RITM NIH SGH NIHE PI CCDC Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab PHLC PHLC

44 1 18 8 0 70 43 156 7 9 366 83 7 229 225 5570 268 31 161 112 377 248 387 128 576 297 289 190 64 110 389 28 212 357 23 86 255 163 82 232 41 230 109 80 19 16 10 12 0 6848

0 0 0 0 1 0 0 0 0 0 0 1 2 2 100 4 1 4 4 2 4 12 3 13 2 9 2 0 1 17 2 3 0 1 5 2 3 0 0 0 3 0 3 0 0 0 0 106

0 0 0 0 0 0 0 0 0 1 0 0 0 0 3 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 4

9 0 3 4 21 10 7 1 2 40 2 0 41 21 582 35 0 16 6 37 28 62 7 103 41 7 14 3 2 32 0 9 39 1 6 30 19 8 23 5 31 14 3 0 1 0 0 743

35 1 15 4 48 33 149 6 7 325 81 6 186 208 4885 229 30 141 102 338 216 311 118 460 254 273 174 61 107 340 26 200 318 21 75 222 141 74 209 36 196 95 74 19 15 10 12 6001

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

100% 100% 100% 100% 94% 97% 98% 100% 94% 95% 100% 100% 95% 98% 60% 52% 77% 80% 73% 60% 20% 64% 79% 55% 90% 43% 70% 61% 91% 69% 98% 42% 32% 87% 81% 74% 37% 78% 74% 71% 40% 72% 67% 55% 63% 20% 97% 65%

20% 0% 16% 44% 24% 21% 3% 14% 22% 9% 3% 0% 15% 9% 9% 11% 0% 7% 5% 8% 9% 13% 5% 14% 13% 2% 7% 5% 2% 6% 0% 4% 10% 4% 6% 10% 9% 9% 9% 11% 13% 11% 4% 0% 3% 0% 0% 9%

29-Jan-14 29-Jan-14 29-Jan-14 29-Jan-14 12-Feb-14 02-Apr-14 25-Feb-14 11-Feb-14 17-Mar-14 08-May-14 18-Feb-14 15-Jan-14 11-Feb-14 18-Mar-14 14-May-14

VIDRL VIDRL VIDRL VIDRL NIID NIID NIID IMR NIID IESR VIDRL NIID SGH NIID NIID Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab CCDC CCDC CCDC CCDC CCDC CCDC CCDC CCDC CCDC

0 0 0 0 0 2 0 0 0 0 3 0 2 4 4 261 12 15 8 12 10 13 18 4 27 4 11 31 0 0 31 10 6 0 2 12 5 7 0 2 1 6 7 3 4 0 0 0 0 276

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

0 1 0 0 2 71 3 6 2 1 4 3 9 1 6 0 9 0 9 4 2 0 2 1 1 0 0 3 3 0 2 74

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

2 1 2 2 0 95 4 6 3 6 4 4 3 0 14 2 1 11 11 6 2 2 7 0 2 2 0 1 2 0 2 102

0 0 0 0 0 4 0 0 0 0 0 0 0 0 0 0 0 4 0 0 0 0 0 0 0 0 0 0 0 0 0 4

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

0 1 0 2 2 77 5 3 3 5 2 6 6 3 7 2 1 2 11 0 2 0 3 4 4 0 1 2 2 3 0 82

0 0 0 0 0 14 0 0 0 0 0 0 0 0 0 0 0 14 0 0 0 0 0 0 0 0 0 0 0 0 0 14

0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 1 0 0 0 0 0 0 3

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%

16-Jan-14 16-Jan-14

PHLC PHLC

1. IESR (Institute of Environmental Science and Research, New Zealand); IMR (Institute of Medical Research, Malaysia); NIH (National Institute of Health, Republic of Korea); NIHE (National Institute of Hygiene and Epidemiology, Ha Noi, Viet Nam); NIID (National Institute of Infectious Diseases, Japan); PHI (Public Health Institute, Mongolia); PHLC (Public Health Laboratory Center, Hong Kong); PI (Pasteur Institute, Ho Chi Minh, Viet Nam); RITM (Research Institute for Tropical Medicine, Philippines); SGH (Singapore General Hospital); VIDRL (Victorian Infectious Diseases Reference Laboratory, Australia) 2. The target of 14 days for the timeliness of virus isolation will be used for all polio laboratories 3. NPEV growing in L20B cells 4. Twenty-two provincial laboratories in China perform ITD from 2013

Polio Bulletin

Table 2B. Laboratory investigation of AFP cases with onset in 2014 and key laboratory indicators Virus isolation results Country National polio laboratory Total no. of AFP L20B cases with positive specimens L20B positive + NPEV NPEV only Pending ≤ 14 Negative days Intratypic % % results differentiation Latest Pending reported specimens / Sequencing positive report date > 14 2 ≤ 14 days for NPEV 1 lab days ≥ 80% No. of isolates referred Type 1 Wild Sabin VDPV Wild Type 2 Sabin Intratypic differentiation (ITD) results Type 3 VDPV Wild Sabin VDPV NPEV 3

Pending ITD

% ITD results Discordant reported ≤ 7 pending days of sequencing receipt ≥ 80%

4 0 0 2 0 17 17 102 3 2 181 53 5 89 70 2358 101 12 98 59 148 108 128 66 225 97 115 79 25 32 172 14 110 150 10 38 128 79 40 93 14 82 65 48 16 5 1 7 0 2910

0 0 4 0 0 0 0 1 0 0 0 0 45 2 0 0 1 1 2 3 0 1 1 10 0 0 0 2 2 3 3 0 1 11 1 0 1 0 0 0 0 0 0 0 0 50

0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1

0 0 3 5 3 0 1 8 3 0 12 8 208 6 0 11 2 20 26 11 1 20 12 2 6 1 2 10 0 0 16 2 2 18 6 6 12 4 11 0 1 0 0 0 0 251

4 1 10 12 89 3 1 160 43 5 71 52 2037 92 12 85 55 127 79 112 65 191 78 103 69 24 28 157 12 86 129 8 35 98 72 31 79 10 71 61 47 15 5 1 7 2495

0 1 0 0 10 0 0 14 7 0 4 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 43

0 0 0 0 0 0 0 0 0 0 2 3 67 1 0 2 1 0 1 1 0 13 6 0 4 0 2 3 0 21 2 0 0 1 0 3 1 0 0 4 0 1 0 0 0 72

88% 100% 94% 100% 100% 100% 100% 91% 93% 100% 100% 93% 62% 54% 75% 91% 65% 75% 15% 56% 82% 72% 79% 43% 86% 78% 62% 66% 96% 42% 26% 90% 92% 45% 45% 72% 86% 71% 56% 86% 64% 70% 100% 0% 95% 65%

0% 0% 12% 26% 3% 0% 50% 4% 5% 0% 13% 12% 7% 6% 0% 8% 3% 10% 20% 7% 1% 7% 13% 2% 7% 4% 7% 4% 0% 0% 9% 15% 4% 12% 6% 12% 12% 21% 13% 0% 1% 0% 0% 0% 0% 7%

14-Mar-14 14-Mar-14 14-Mar-14 14-Mar-14 10-Jul-14 14-Jul-14 11-Jul-14 07-Jul-14 04-Jul-14 21-Jul-14 18-Jul-14 15-Jul-14 09-Jul-14 04-Jul-14 09-Jul-14

VIDRL VIDRL VIDRL VIDRL NIID NIID NIID IMR NIID IESR RITM NIH SGH NIHE PI Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab CCDC CCDC CCDC CCDC CCDC CCDC CCDC CCDC CCDC

0 0 0 0 0 8 0 0 0 0 2 0 0 0 0 126 4 5 0 6 4 5 5 0 2 2 26 0 0 0 4 6 8 10 0 4 24 3 2 4 0 0 2 0 0 0 0 0 0 136

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

0 0 31 0 2 2 2 0 2 0 0 2 6 2 0 0 4 2 7 0 0 0 0 31

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

8 2 48 2 0 2 2 2 2 0 0 0 14 0 2 4 4 2 7 1 2 2 0 58

0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 2

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

0 0 45 2 3 2 0 3 1 0 2 0 6 2 4 2 2 0 10 2 0 2 2 45

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

0 0 3 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 2 0 0 0 3

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

100% 100% 96% 100% 100% 100% 50% 100% 100% 100% 100% 100% 95% 100% 100% 100% 100% 100% 93% 100% 100% 100% 100% 96%

28-May-14 28-May-14

PHLC PHLC

Polio Bulletin

Table 3A. Laboratory confirmation of polio isolates from other sources in 2013 Non-AFP cases Country Intratypic Total number Total number differentiation of non-AFP of non-AFP lab 2 cases tested cases with polio isolates for polio Type 1 Wild Sabin VDPV Wild Type 2 Sabin VDPV Wild Type 3 Sabin NPEV Discordant Total number Pending grown pending of samples ITD sequencing processed VDPV in L20B Total number of samples with polio isolates Type 1 Wild Sabin VDPV

Environmental samples Type 2 Wild Sabin VDPV Wild Type 3 Sabin NPEV Discordant Pending grown pending ITD sequencing VDPV in L20B

Australia Japan Malaysia Mongolia New Zealand Philippines Republic of Korea Singapore Viet Nam, North Viet Nam, South China (total) China, Anhui China, Beijing China, Fujian China, Gansu China, Guangdong China, Guangxi China, Hebei China, Heilongjiang China, Henan China, Hunan China, Jiangsu China, Jiangxi China, Jilin China, Shaanxi China, Shandong China, Shanghai China, Shanxi China, Sichuan China, Tianjin China, Xinjiang China, Yunnan China, Zhejiang China, Chongqing China, Guizhou China, Hainan China, Hubei China, Liaoning China, Neimongol China, Ningxia China, Qinghai China, Tibet Hong Kong (China) Total

VIDRL NIID IMR PHI IESR VIDRL NIID SGH NIID NIID Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab CCDC CCDC CCDC CCDC CCDC CCDC CCDC CCDC CCDC PHLC

269 0 0 158 0 6 0 0 0 0 28 0 0 0 7 1 0 2 2 0 0 0 2 0 0 2 2 0 2 1 2 0 0 0 0 1 0 0 3 1 0 0 1 462

1 0 6 28 7 1 2 2 2 2 2 2 1 2 1 3 1 1 36

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

0 0 5 15 7 0 2 0 0 2 1 1 1 0 0 0 1 1 21

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

1 0 1 11 4 0 0 0 1 1 0 0 0 2 1 1 1 0 13

0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

0 0 1 13 4 0 0 2 1 1 1 1 1 0 0 2 0 0 14

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

0 56 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 56

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

0 0 33 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 33

4 4

0 0

1 1

0 0

2 2

0 0

1 1

0 0

27 27

0 0

1. Based on year of collection of sample, if available. Otherwise, based on year of receipt at reference laboratory. 2. CCDC (Chinese Center for Disease Control and Prevention, China); IESR (Institute of Environmental Science and Research, New Zealand); IMR (Institute of Medical Research, Malaysia); NIID (National Institute of Infectious Diseases, Japan); PHI (Public Health Institute, Mongolia); PHLC (Public Health Laboratory Center, Hong Kong); SGH (Singapore General Hospital); VIDRL (Victorian Infectious Diseases Reference Laboratory, Australia)

Polio Bulletin

Table 3B. Laboratory confirmation of polio isolates from other sources in 2014 Non-AFP cases Country Intratypic Total number Total number differentiation of non-AFP of non-AFP lab 2 cases tested cases with polio isolates for polio Type 1 Wild Sabin VDPV Wild Type 2 Sabin VDPV Wild Type 3 Sabin NPEV Discordant Total number Pending grown pending of samples ITD sequencing processed VDPV in L20B Total number of samples with polio isolates Type 1 Wild Sabin VDPV

Environmental samples Type 2 Wild Sabin VDPV Wild Type 3 Sabin Discordant NPEV Pending pending grown ITD sequencing VDPV in L20B

10 0 0 132 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 144

0 0 0 1 1 1

0 0 0 0 0 0

0 0 0 1 1 1

0 0 0 0 0 0

0 13 0 0 0 13

0 0 0 0 0 0

0 0 9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 9

6 6

0 0

1 1

0 0

5 5

0 0

4 4

0 0

Polio Bulletin

Table 4. Vaccine-derived poliovirus, 2000–2013 Country Cambodia iVDPV1 (1 case) aVDPV1 (1 case) aVDPV3 (1 case) aVDPV3 (1 case)

2000

2001

2002

2003

2004

2005 cVDPV3 (1 case)

2006 cVDPV3 (1 case)

2007

2008

2009

2010

2011

2012

2013

China

aVDPV1 (1 case)

cVDPV1 (2 cases) aVDPV1 (1 case) aVDPV1 (3 cases) ?VDPV1 (4 cases) iVDPV2 (1 case) ?VDPV1 (7 cases) ?VDPV1 (1 case) ?VDPV2 (1 case) VDPV3 (1 case) ?VDPV? (3 cases) ?VDPV? (1 case) aVDPV2 (1 case) ?VDPV? (2 cases) ?VDPV? (1 case) ?VDPV3 (1 case)

aVDPV2 (1 case)

aVDPV1 (1 case) aVDPV1 (1 case) aVDPV2 (3 cases) aVDPV2 (5 cases) aVDPV2 (2 cases) aVDPV2 (1 case) cVDPV2 (2 cases) aVDPV3 (2 cases) cVDPV2 (3 cases) iVDPV2 + iVDPV3 (1 case) iVDPV2 (2 cases) iVDPV2 + iVDPV3 (1 case) iVDPV3 (1 case)

Hong Kong (China) Japan Lao People's Democratic Republic Mongolia Philippines Viet Nam cVDPV1 (3 cases)

aVDPV2 (2 cases)

Polio Bulletin

Informations clés

Organisation Organisation mondiale de la santé (OMS)

Type de document Technical Documents

Date d'adoption 21 juillet 2014

Source Organisation mondiale de la santé